Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Tarah Ballinger

Associate Professor of Medicine

Indiana University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States

About

Tarah Ballinger is an Assistant Professor of Clinical Medicine at Indiana University School of Medicine, USA. Her research focuses on exercise oncology, chemotherapy efficacy in breast cancer, and the clinical utility of circulating tumor cells in metastatic conditions. Recent publications highlight her expertise in the intersection of physical activity and cancer treatment outcomes, as well as innovative approaches to managing fatigue among breast cancer survivors.

Articles (17)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tarah Ballinger

Research Interests

Explore related searches

About

Articles (17)

Impact of patient‐reported taxane‐induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG‐ACRIN EAZ171

A phase 1 study of ASTX727 plus talazoparib in patients with triple‐negative or hormone resistant/HER2‐negative metastatic breast cancer

NCCN Guidelines® Insights: Survivorship, Version 2.2025

Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer

A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer

Racial differences in breast cancer-specific mortality and CVD-specific mortality after breast cancer in post-menopausal women.

Purpose in life and mortality among breast cancer survivors.

Exercise load monitoring: integrated approaches to advance the individualisation of exercise oncology.

Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.

Evaluation of an Extended-duration Chemoprophylaxis Regimen for Venous Thromboembolism after Microsurgical Breast Reconstruction.

Landmark trials in the medical oncology management of metastatic breast cancer.

Physical activity and risk of benign proliferative epithelial disorders of the breast, in the Women's Health Initiative.

A Personalized, Dynamic Physical Activity Intervention Is Feasible and Improves Energetic Capacity, Energy Expenditure, and Quality of Life in Breast Cancer Survivors.

Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer-Is Not Worse Good Enough?

Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

Protocol of a randomized trial of acceptance and commitment therapy for fatigue interference in metastatic breast cancer.

Collaborators (9)

Fengmin Zhao

Shelley Johns

Evgenios Evgeniou

Robert Wesolowski

Diane Von Ah

Kathy Miller

Hyo Sik Jang

Alexandra Thomas

Stefania Morganti

Make your next move.